Novartis strikes about $7.8 billion mRNA deal with China's Abogen

By Reuters News

- Chinese biotech company Abogen said on Friday it signed a licensing and option agreement worth about $7.8 billion with Swiss drug maker Novartis NOVN.S to advance RNA-based therapy.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk